Global Preventive Asthma Drugs Market 2015-2019
According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations.
Technavio's analysts forecast the global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma:
Technavio Announces the Publication of its Research Report – Global Preventive Asthma Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Preventive Asthma Drugs Market: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck and Novartis
Other Prominent Vendors in the market are: Abbott, Amgen, AptarGroup, Biotest, Boehringer Ingelheim, Chiesi Farmaceutici, Cytos, Dainippon Sumitomo, Medicinova, Mylan, Novartis, Orchid Chemicals and Pharmaceuticals, Pfizer, Rottapharm Madaus, Skyepharma, Sosei, Sunovion, Teva Pharmaceutical, Theravance, Vectura
Commenting on the report, an analyst from Technavio’s team said: “The popularity of combination therapies for the treatment of asthma will help in the market's growth. Drugs that fall under the category of ICS, LABA, and leukotriene receptor antagonists are frequently prescribed by physicians to control asthma.”
According to the report, the market is set to grow because of the high prevalence of asthma worldwide. The demand for drugs to treat and prevent asthma presents an opportunity to develop a therapy with better efficacy and safety profiles. The market expects to launch its robust pipeline of drug candidates for the management of asthma during the forecast period.
Further, the report states that growth may be hampered because of the disease's unknown origins. Finding a drug that targets the root cause of the disease has been difficult to find. Also, the patent expiry of some of the highest-selling drugs has resulted in the entry of generics, affecting market growth.
AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Abbott, Amgen, AptarGroup, Biotest, Boehringer Ingelheim, Chiesi Farmaceutici, Cytos, Dainippon Sumitomo, Medicinova, Mylan, Novartis, Orchid Chemicals and Pharmaceuticals, Pfizer, Rottapharm Madaus, Skyepharma, Sosei, Sunovion, Teva Pharmaceutical, Theravance, Vectura